This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by George, S. Articles by Socinski, M. A. Search for Related Content PubMed PubMed Citation Articles by George, S. Articles by Socinski, M. A.

Adjuvant Chemotherapy for Resected Non-Small Cell Carcinoma of the Lung: Why We Still Don't Know

Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Thoracic Surgery, Departments of Medicine, Surgery and Biostatistics, School of Medicine and Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Correspondence: Mark A. Socinski, M.D., CB# 7305, University of North Carolina, Chapel Hill, NC 27599-7305, USA. Telephone: 919-966-4431; Fax: 919-966-6735; e-mail: socinski{at}med.unc.edu

The role of adjuvant chemotherapy in resected non-small cell carcinoma of the lung (NSCLC) remains controversial. A critical review of the 11 cisplatin-based randomized trials addressing this issue was performed using methodology adapted from the CONSORT statement. The 11 trials were divided into those that included predominantly node-negative patients (n = 5) and those that included predominantly node-positive patients (n = 6). In the node-negative trials, which included 1,084 evaluable patients, no evidence of heterogeneity of treatment effect between the trials was found. The composite five-year survival rate for chemotherapy patients was 61% versus 55% for control patients, which reached marginal significance (p = 0.06). In the node-positive trials, which included 880 evaluable patients, a marginal lack of homogeneity of treatment effect between trials was found (p = .013). The composite two-year survival rate for chemotherapy patients was 48% versus 40% for control patients, which reached marginal significance (p = 0.06). Although not definitive, these trials suggest a benefit to postoperative adjuvant chemotherapy in resected NSCLC. The cumulative experience of the 11 trials is notable for: A) the small number of patients; B) heterogenous patient populations; C) substandard chemotherapy regimens; D) inadequate chemotherapy delivery, and E) less than optimally executed clinical trials. The 11 trials are discussed in detail, and recently completed and ongoing trials of adjuvant chemotherapy in resected NSCLC are reviewed.

Key Words. Non-small cell lung cancer • Adjuvant chemotherapy

This article has been cited by other articles:

				K. M.W. Pisters, W. K. Evans, C. G. Azzoli, M. G. Kris, C. A. Smith, C. E. Desch, M. R. Somerfield, M. C. Brouwers, G. Darling, P. M. Ellis, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non Small-Cell Lung Cancer Guideline J. Clin. Oncol., December 1, 2007; 25(34): 5506 - 5518. [Abstract] [Full Text] [PDF]

				N. Alam, G. Darling, F. A. Shepherd, J. A. Mackay, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta Postoperative Chemotherapy in Nonsmall Cell Lung Cancer: A Systematic Review. Ann. Thorac. Surg., May 1, 2006; 81(5): 1926 - 1936. [Abstract] [Full Text] [PDF]

				J. H. Park, C.-T. Lee, H. W. Lee, H. J. Baek, J. I. Zo, and Y. M. Shim Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1086 - 1091. [Abstract] [Full Text] [PDF]

				R. B. Diasio Adjuvant Chemotherapy for Adenocarcinoma of the Lung -- Is the Standard of Care Ready for Change? N. Engl. J. Med., April 22, 2004; 350(17): 1777 - 1779. [Full Text] [PDF]

				G. V. Scagliotti, R. Fossati, V. Torri, L. Crino, G. Giaccone, G. Silvano, M. Martelli, M. Clerici, F. Cognetti, and M. Tonato Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer J Natl Cancer Inst, October 1, 2003; 95(19): 1453 - 1461. [Abstract] [Full Text] [PDF]

				A. T. Schroen, F. C. Detterbeck, R. Crawford, M. P. Rivera, and M. A. Socinski Beliefs Among Pulmonologists and Thoracic Surgeons in the Therapeutic Approach to Non-small Cell Lung Cancer Chest, July 1, 2000; 118(1): 129 - 137. [Abstract] [Full Text] [PDF]